Litigation Details for MITSUBISHI TANABE PHARMA CORPORATION v. SANDOZ INC. (D.N.J. 2017)
✉ Email this page to a colleague
MITSUBISHI TANABE PHARMA CORPORATION v. SANDOZ INC. (D.N.J. 2017)
| Docket | 3:17-cv-05319 | Date Filed | 2017-07-20 |
| Court | District Court, D. New Jersey | Date Terminated | 2021-04-05 |
| Cause | 15:1126 Patent Infringement | Assigned To | Freda L. Wolfson |
| Jury Demand | None | Referred To | Douglas Arpert |
| Parties | CILAG GMBH INTERNATIONAL | ||
| Patents | 6,414,126; 6,515,117; 6,765,001; 7,943,788; 8,222,219; 8,785,403 | ||
| Attorneys | JAY R. DESHMUKH | ||
| Firms | Lerner David Littenberg Krumholz and Mentlik LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in MITSUBISHI TANABE PHARMA CORPORATION v. SANDOZ INC.
Details for MITSUBISHI TANABE PHARMA CORPORATION v. SANDOZ INC. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-07-20 | External link to document | |||
| 2017-07-20 | 1 | Complaint | infringement of United States Patent No. 7,943,788 (“the ’788 patent”), United States Patent No. 8,222,219 (“the…the ’219 patent”), and United States Patent No. 8,785,403 (“the ’403 patent”) (collectively, “the patents-in-suit….S.C. § 355(b)(l), the ’788 patent, the ’219 patent, and the ’403 patent are listed in the United States… THE PATENTS-IN-SUIT 19. On May 17, 2011, the ’788 patent, titled “Glucopyranoside…the ’788 patent. 21. JNV is an exclusive sublicensee of the ’788 patent. | External link to document |
| 2017-07-20 | 128 | Stipulation and Order | it is the owner of United States Patent No. 7,943,788 (“the ’788 patent”). WHEREAS, Sandoz has filed Abbreviated…District Court for the District of New Jersey for patent infringement based on Sandoz’s filing of ANDA …2017 5 April 2021 3:17-cv-05319 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2017-07-20 | 166 | Trial Brief | disclosed in the ’117 patent ’126 patent U.S. Patent No. 6,414,126 …Example 10 Example 10 of U.S. Patent No. 6,414,126 FDA United States …788 patent, claim 22 of the ’219 patent, and claim 26 of the ’403 patent BMS…Seiyaku Co., Ltd. patents-in-suit U.S. Patent No. 7,943,788 (“the ’788 patent”), … U.S. Patent No. 8,222,219 (“the ’219 patent”), and U.S. Patent No. 8,785,403 | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
